FOXG1 Research Foundation CFO and dad to Crosby reflects on what the $4.9M CIRM grant really means to the parent-led patient organization that started the journey with little hope for a future treatment, to now having a gene replacement therapy beginning first in-human clinical trial.

This week, FRF was awarded a $4.9 million grant from CIRM to support our Phase 1/2 gene therapy clinical trial. The funding is transformative for our organization and our ability to advance FRF-001, our AAV9 gene therapy program.

But what means even more to me is the validation behind it.

The FOXG1 Research Foundation has been awarded a $4,9M grant from the California Institute for Regenerative Medicine (CIRM) to advance FRF-001, our gene therapy, through its Phase 1/2 patient clinical trial.